Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020138791 - SUSTAINED-RELEASE PREPARATION COMPRISING TOFACITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND MANUFACTURING METHOD THEREFOR

Publication Number WO/2020/138791
Publication Date 02.07.2020
International Application No. PCT/KR2019/017717
International Filing Date 13.12.2019
IPC
A61K 9/20 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61K 31/519 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
Applicants
  • 주식회사 대웅제약 DAEWOONG PHARMACEUTICAL CO., LTD. [KR]/[KR]
Inventors
  • 박경희 PARK, Kyung Hee
  • 윤재희 YOON, Jae Hee
Agents
  • 특허법인디케이피 DKP INTERNATIONAL PATENT & LAW FIRM
Priority Data
10-2018-017210328.12.2018KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) SUSTAINED-RELEASE PREPARATION COMPRISING TOFACITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND MANUFACTURING METHOD THEREFOR
(FR) PRÉPARATION À LIBÉRATION PROLONGÉE COMPRENANT DU TOFACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ASSOCIÉ ET SON PROCÉDÉ DE FABRICATION
(KO) 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법
Abstract
(EN)
The present invention relates to a sustained-release preparation comprising tofacitinib or a pharmaceutically acceptable salt thereof, a release sustaining agent, and a hydrophilic binder. Disclosed is a sustained-release preparation in a hydrophilic matrix formulation form that shows in vivo effects as good as those of an immediate release preparation at a lower dose than that of currently commercialized sustained-release products, that is, at a dose of 10 mg and which is relatively simple in the manufacturing procedure thereof and as such, exhibits excellent productivity and economical benefit.
(FR)
La présente invention concerne une préparation à libération prolongée comprenant du tofacitinib ou un sel pharmaceutiquement acceptable associé, un agent de prolongement de libération et un liant hydrophile. L'invention concerne une préparation à libération prolongée dans une forme de formulation de matrice hydrophile qui présente des effets in vivo aussi bons que ceux d'une préparation à libération immédiate à une dose inférieure à celle des produits à libération prolongée actuellement commercialisés, à savoir, à une dose de 10 mg, et qui est relativement simple dans son procédé de fabrication et présente ainsi une excellente productivité et un avantage économique.
(KO)
본 발명은 토파시티닙 또는 그의 약제학적으로 허용되는 염, 서방화제 및 친수성 결합제를 포함하는 서방성 제제에 관한 것으로, 현재 시판중인 서방성 제품보다 적은 함량 즉, 10mg으로 생체내에서 속방성 제제와 동등한 효과를 나타내며, 제조 과정이 비교적 간단하여 생산성 및 경제성이 우수한 친수성 매트릭스 제형의 서방성 제제를 개시한다.
Also published as
Latest bibliographic data on file with the International Bureau